Thymic peptides for treatment of cancer patients

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2011, Pages

  Wolf, Elke ^a   Milazzo, Stefania ^a   Boehm, Katja ^a   Zwahlen, Marcel ^b   Horneber, Markus ^a  

^a KLINIKUM NÜRNBERG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LOMUSTINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NITROSOUREA; PLACEBO; PREDNISONE; PROCARBAZINE; THYMOPENTIN; THYMOSIN ALPHA1; THYMOSIN FRACTION 5; THYMOSTIMULIN; VINCRISTINE; VINDESINE; VINORELBINE TARTRATE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; PEPTIDE; THYMOSIN; THYMUS EXTRACT;

ADVANCED CANCER; BONE ATROPHY; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EXANTHEMA SUBITUM; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INFECTION; INJECTION SITE INFECTION; INJECTION SITE REACTION; LIVER CELL CARCINOMA; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; METASTASIS; METASTATIC BREAST CANCER; MOUTH CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMALL CELL LUNG CANCER; SOLID MALIGNANT NEOPLASM; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; CHEMISTRY; DRUG EFFECT; FEMALE; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; NEOPLASM; THYMUS;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOCOMPROMISED HOST; MALE; NEOPLASMS; PEPTIDES; THYMOPENTIN; THYMOSIN; THYMUS EXTRACTS; THYMUS GLAND;

EID: 79953011511     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003993.pub3     Document Type: Review

References (79)

1. Airoldi M, Gabriele P, Penani F, Brando V, Melano A. Chemioterapia versus chemioimmunoterapia con Timostimulina nei carcinomi avanzati del cavo orale: risultati clinici di uno studio randomizzato. Recenti Progressi in Medicina 1987;78 Suppl 6:67-70. 3323646
2. Bedikian AY, Patt YZ, Murphy WK, Umsawasadi T, Carr DT, Hersh EM, et al. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy. American Journal of Clinical Oncology 1984;7(5):399-404. 3323648
3. Canovas Fernandez A, Gonzalez de Zarate P, Alonso Alonso J, Aguirre Errasti C. [Thymostimulin as an adjuvant to antineoplastic chemotherapy. Experience with patients with myeloma and lymphoma]. Revista Clinica Espanola 1988;183(7):340-3. 3323650
4. Canovas Fernandez A, Alonso Alonso J, Gonzalez de Zarate P, Garcia Masdevall MD, Rinon Martinez-Gallo M, Aguirre Errasti C. [The use of thymostimulin in lymphoma and myeloma patients]. Anales de Medicina Interna 1991;8(2):69-73. 3323652
5. Cheng S, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 2004;51(59):1445-7. 3323654
6. Chretien PB, Lipson SD, Makuch R, Kenady DE, Cohen MH, Minna JD. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treatment Reports 1978;62(11):1787-90. 3323656
7. Cohen MH, Chretien PB, Ihde DC, Fossieck BE, Makuch R, Bunn PA, et al. Thymosin fraction V and intensive combination chemotherapy. Journal of the American Medical Association 1979;241:1813-5. 3323657
8. Lipson SD, Chretien PB, Makuch R, Kenady DE, Cohen MH. Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course. Cancer 1979;43(3):863-70. 3323658
9. Del Giacco GS, Mantovani G, Cengiarotti L, Puxeddu G, Pischedda A, Di Tucci A, et al. Secondary immunodeficiency in advanced lung cancer: effects of chemotherapy plus thymostimulin in immunodepressed patients: updating results. International Journal of Tissue Reactions 1984;6(6):499-504. 3323660
10. Del Giacco GS, Mantovani G, Pilidi G, et al. Thymic factors in lung cancer. In: Nagel G, Schioppacassi G, Schuff-Werner P editor(s). Thymic hormones in oncology. Roma: Ares Serono Symposia, 1988:149-56. 3323661
11. De Serdio JL, Villar A, Alvarez IE, Gil-Cubelo JA, Suner M, Hernandez R, et al. [The effects of thymostimulin in a protocol of concurrent hyperfractionated carboplatin and irradiation]. Acta Otorrinolaringologica Espanola 1997;48(6):487-92. 3323663
12. Federico M, Gobbi PG, Mretti G, Avanzini P, di Renzo N, Cavanna L, et al. Effects of thymostimulin with combination chemotherapy in patients with aggressive Non-Hodgkin lymphoma. A report from the Italian Lymphoma Study Group (GISL). American Journal of Clinical Oncology 1995;18(1):8-14. 3323665
13. Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N. A prospective randomized trial of thymopentin versus granulocyte-colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Research 1994;14(2B):731-4. 3323667
14. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology International 2009;3:480-9. 3323669
15. GISOT (Gruppo Italiano di Studio Sugli Ormoni Timici). [Efficacy and tolerability of thymopoietin in patients at risk of infection]. Recenti Progressi in Medicina 1987;78(7-8):358-64. 3323671
16. Gonnelli S, Petrioli R, Cepollaro C, Palmieri R, Aquino A, Gennari C. Thymostimulin in association with chemotherapy in breast cancer patients with bone metastases. Clinical Drug Investigation 1995;9(2):79-87. 3323673
17. Guzman Machado CA, Verruno L, Ribas MC. Adjuvant therapy with thymic factors in solid tumours. In: Nagel G, Schioppacassi G, Schuff-Werner P editor(s). Thymic Hormones in Oncology. Roma: Ares serono Symposia, 1988:121-32. 3323675
18. Iaffaioli RV, Caponigro F, Facchini G, Tortoriello A, Panelli G, Muto P, et al. Immunological and clinical effects of thymostimulin in patients with locally advanced non-small-cell lung cancer treated with combined chemoradiotherapy. Drug Investigation 1994;7:209-14. 3323677
19. Luzi G, Tropea F, Siminara R, et al. Clinical and immunological evaluation in non-resectable lung cancer patients treated with thymostimulin. Serono Symposia Publications 1984;16:309-20. 3323679
20. Macchiarini P, Danesi R, Del Tacca M, Angeletti CA. Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Research 1989;9:193-6. 3323681
21. Camerini R, Mackiewicz A, Testori A, Trefzer U, Jassem J, Ferraresi V, et al. A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results. Journal of Clinical Oncology 2007;25(18S):8535. 3323683
22. Camerini R, Mackiewicz A, Testori A, Trefzer U, Jassem J, Ferraresi V, et al. A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results. Powerpoint presentation ASCO Annual Meeting June 1-5, 2007, Chicago. 3323684
23. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, et al. Large randomized study of thymosin (alpha) 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology 2010;[Epub ahead of print]:1780-7. 3323685
24. Mantovani G, Coiana A, Zucca MV, Sanna GP, Floris C, Sulis E, et al. [Results of a controlled clinical protocol in the treatment of patients with operable breast carcinoma with positive axillary lymph nodes. Comparison of a chemotherapeutic regimen with a chemo-immunotherapeutic regimen]. Recenti Progressi in Medicina 1988;79(12):513-8. 3323687
25. Mustacchi G, Pavesi L, Milani S, Iaffaioli V, Caraco A, Comella G, et al. High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial. Anticancer Research 1994;14:617-20. 3323689
26. Pavesi L. Fluorouracil (F), with and without high-dose folinic acid (HDFA) plus epirubicin (E) and cyclophosphamide (C): FEC versus HDFA-FEC plus or minus thymostimulin (TS) in metastatic breast cancer: results of a multicenter study. European Journal of Cancer 1993; Vol. 29 A Suppl:77. 3323691
27. Salvati F, Pallotta G, Antilli A, Nunziati F, De Marinis F, Lucchesi M. [MACC plus Thymostimulin (TP-1 Serono) therapy of small cell bronchogenic carcinoma. Clinico-immunologic evaluation of the results of a randomized trial]. Giornale Italiano di Chemiotherapia 1984;31:185-9. 3323693
28. Sanchiz F, Milla A. A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of heamatological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy. European Journal of Cancer 1996;32 A:52-6. 3323695
29. Scher HI, Shank B, Geller N, Pinsky C, Gralla R, Kelsen D, et al. Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer Research 1988;48(6):1663-70. 3323697
30. Schulof RS, Lloyd MJ, Cleary PA, Palaszynski SR, Mai DA, Cox JW, et al. A randomized trail to evaluate the immunorestorative properties of synthetic thymosin-a in patients with lung cancer. Journal of Biological Response Modifiers 1985;4(2):147-58. 3323699
31. Wara WM, Neely MH, Amman AJ, Wara DW. Biologic modifications of immunologic parameters in head and neck cancer patients with thymosin fraction V. In: Goldstein AL, Chirigos MA editor(s). Lymphokines and Thymic Hormones: their potential utilization in cancer therapeutics. Raven Press, New York, 1981:257-62. 3323701
32. Azizi E, Brenner HJ, Shoham J. Postoperative adjuvante behandlung von patienten mit malignem melanom durch die thymusfaktor thymostimulin. Arzneimittelforschung 1984;34(II):1043-6. 3323703
33. Bernengo MG, Fra P, Lisa F, Meregalli M, Zina G. Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course. Clinical Immunology and Immunopathology 1983;28(3):311-24. 3323705
34. Bernengo MG, Lisa F, Meregalli M, De Matteis A, Zina G. The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up. Cancer 1983;52(10):1841-8. 3323706
35. Cartia GL. [Evaluation of the effects of thymopentin on the incidence of leucopenia in patients treated with chemotherapy for breast carcinoma] Valutazione degli effetti di Timopentina sullincidenza di leucopenia in pazienti trattate con chemioterapia per carcinom mammario. Minerva Medica 1990;81(11):815-7. 3323708
36. Chen J, Huang F, Zheng X, Chen L, Qin S, Li G, et al. Thymosin alpha 1 positively alters quality of life in chemotherapy treated patients. Proceedings American Society of Clinical Oncology 2000; Vol. 1. 3323710
37. De Maria D, Falchi AM, Armaroli L, Balli M, Bortolus R, Busutti L, et al. T-lymphocyte subsets in cancer patients undergoing radiotherapy and their recovery after thymostimulin treatment. A cooperative study. RAYS 1993;18:438-53. 3323712
38. Denaro A, Stivala F, Mazzarino MC. [Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy and radiotherapy]. Acta Otorhinolaryngologica Italica 1994;14:611-25. 3323714
39. Holowiecki J, Duraj M, Rudzka E, Jarczok K, Krawczyk M, Holowiecka B, et al. Cooperative randomized studies on the treatment of adult acute leukemia in Poland. A comparison of two remission induction regimes and two maintenance regimes for AML. Folia Haematologica 1984;111(2):201-7. 3323716
40. Iaffaioli RV, Frasci G, Tortora G, Ciardiello F, Nuzzo F, Scala S, et al. Effect of thymic extract "thymostimulin" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus 1988;12:69-75. 3323718
41. Kreuser ED. [Randomised, double-blind trial to compare low-molecular thymic peptides, 5-fluorouracil and folic acid with placebo, 5-fluorouracil and folic acid in patients with metastasised colorectal cancer] [Randomisierter, doppelblinder Therapievergleich von niedermolekularen Thymus- Peptiden, 5-Fluorouracil und Folinsäure versus Placebo, 5-Fluorouracil und Folinsäure bei Patienten mit metastasiertem kolorektalen Karzinom im Stadium UICC IV (pT1-4, N0-2, M1)]. Internet ("This trial was identified via internet databases. In this multicenter study patients were randomised to receive thymuvocal or placebo. The pharmaceutical company (DR Schmidt) supposed to be in charge of did not provide information about this study".) 1998. 3323720
42. Liberati AM, Ballatori E, Fizzotti M, Schippa M, Cini L, Cinieri S, et al. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkins disease in complete remission. Cancer Immunology, Immunotherapy 1998;26:87-93. 3323722
43. Mantovani G, Ghiani M, Bianchi A, Curreli L, Contini L, Maccio A, et al. [The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage] [Valutazione immunologica di un approccio terapeutico combinato (chemio + radioterapia +/- chirurgia) includente l'immunoterapia nelle neoplasie del distretto cervico-facciale in stadio avanzato.]. Recenti Progressi in Medicina 1995;86:8-16. 3323724
44. Migeod F. [Results of a prospective randomised study on the immunologic effects of the xenogenic organ lysates Ney Tumorin-Sol and Neythymun compared to placebo] [Ergebnisse einer prospektiv randomisierten Studie über immunologische Wirkungen der xenogenen Organlysate Ney Tumorin-Sol und Neythymun in Vergleich zu einem Placebo]. Therapiewoche 1985;35, 26A:115-20. 3323726
45. Munno I, Marinaro M, Gesario A, Cannuscio B, Michel Y, Paulling E. Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias. Clinical and Diagnostic Laboratory Immunology 1995;2:503-5. 3323728
46. Quang-Xing Ni, Fu DI, Yu XJ, Xu J, Hua JM, Chen W, et al. Efficacy of thymalfasin on cellular immune function and chemotherapy induced toxicity in pancreatic cancer. Proceedings American Society of Clinical Oncology 2001. 3323730
47. Shoham J. The effect of the thymic factor thymostimulin on survival rate, immune function and resistance to infection in experimental and clinical cancer. Thymic Hormones in Oncology. Ares Serono Symposia, 1988:45-57. 3323732
48. Surico N, Tavassoli K. Effect of immunostimulating therapy on the immunocompetent system in breast carcinoma. Panminerva Medica 1992;34:172-80. 3323734
49. Tetti M, Tomassone W, Milani R, Paste M, Vaudano G, Rolfo A, et al. Uso di un farmaco immunomodulatore nella prevenzione della comparsadi episodi infettivi a carico delle vie urinarie in pazienti affette da neoplasie ginecologiche e sottoposte a ciclo TCT. Recenti Progressi in Medicina 1987;78 Suppl 6:51-3. 3323736
50. Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, et al. Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer 2010;10:457. 3323738
51. Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Current Opinion in Investigational Drugs 2002;3(5):698-707.
52. Bodey B, Bodey BJr, Siegel SE, Kaiser HE. Review of thymic hormones in cancer diagnosis and treatment. International Journal of Immunopharmacology 2000;22(4):261-73.
53. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute 2003;95(22):1674-80.
54. Chretien PB, Lipson SD, Makuch R, Kenady DE, Cohen MH, Minna JD. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treatment Reports 1978;62(11):1787-90.
55. Costanzi JJ, Gagliano RG, Delaney F, Harris N, Thurman GB, Sakai H, et al. The effect of thymosin on patients with disseminated malignancies. A phase I study. Cancer 1977;40(1):14-9.
56. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) - Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/About.html May 28, 2009.
57. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002;3(11):991-8.
58. Ernst E. Thymus therapy for cancer? A criteria-based, systematic review [see comments]. European Journal of Cancer 1997;33(4):531-5.
59. Falchetti R, Bergesi G, Eshkol A, Cafiero G, Adorini L, Caprino L. Pharmacological and biological properties of a calf thymus extract (TP-1). Drugs Under Experimental and Clinical Research 1977;3:39-46.
60. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proceedings of the National Academy of Sciences of the United States of America 1966;56(3):1010-7.
61. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences of the United States of America 1977;74(2):725-9.
62. Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 1979;204(4399):1309-10.
63. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin à1. Expert Opinion on Biological Therapy 2009;9(5):593-608.
64. Grothey A, Düppe J, Hasenburg A, Voigtmann R. Anwendung alternativmedizinischer methoden durch onkologische patienten. Deutsche Medizinische Wochenschrift 1998;123:923-9.
65. Hannappel E, Huff T. The thymosins prothymosin à, parathymosin, and á-thymosins: structure and function. Vitamins and Hormones. Academic press, 2003:2-296.
66. Hardell L, Nordenstam M, Moqvist I, Lindberg L. A new study of patients with cancer in Umea alternative medicine is no alternative [Ny studie av cancerpatienter i Umea: alternativmedicin inget alternativ.]. Lakartidningen 1998;95(18):2092-5.
67. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Vol. available from www.cochrane-handbook.org, The Cochrane Collaboration, 2009.
68. Kirkwood BR, Sterne JAC. Essential medical statistics. Essential medical statistics. Oxford: Blackwell Science Ltd, 2003:Chapter 22.
69. Kullmer U, Stenger K, Milch W, Zygmunt M, Sachsse S, Münstedt K. Self-concept, body image, and use of unconventional therapies in patients with gynaecological malignancies in the state of complete remission and recurrence. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1999;82(1):101-6.
70. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting Results of Cancer Treatment. Cancer 1981;47(1):207-14.
71. Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dnser M, Richter R, et al. Use of alternative / complementary therapy in breast cancer patients - a psychological perspective. Supportive Care in Cancer 2001;9:267-74.
72. Rost KL, Wierich W, Masayuki F, Tuthill CW, Horwitz DL, Herrmann WM. Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 1999;37(1):51-7.
73. Schlesinger DH, Goldstein G, Scheid MP, Boyse EA. Chemical synthesis of a peptide fragment of thymopoietin II that induces selective T cell differentiation. Cell 1975;5(4):367-70.
74. Schulof RS. Thymic peptide hormones: basic properties and clinical applications in cancer. Critical Reviews in Oncology/Hematology 1985;3(4):309-76.
75. Sehouli J. How frequently do female patients with gynecological cancers use unconventional cancer therapies?. Gynecologic Oncology 2000;79(2):336-7.
76. Seybold WD, McDonald JR, Clagett OR, Good CA. Tumors of the thymus. Journal of Thoracic Surgery 1950;20(2):195-215.
77. Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS. Thymopentin and splenopentin as immunomodulators. Current status. Immunologic Research 1998;17(3):345-68.
78. Soellner W, Zingg-Schir M, Rumpold G, Fritsch P. Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. Archives of Dermatology 1997;133(3):316-21.
79. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92(3):205-16.